Q32 bio inc QTTB.US 總覽分析
)QTTB 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
QTTB 近期報酬表現
5.13%
Q32 bio inc
3.56%
同產業平均
1.47%
S&P500
與 QTTB 同產業的標的表現
- BIOA Bioage labs inc價值 -趨勢 3 分波段 4 分籌碼 2 分股利 1 分查看更多
QTTB 公司資訊
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7R?), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.